MAXONA PHARMACEUTICALS EMERGES FROM STEALTH AS IT ACHIEVES MILESTONE IN DEVELOPMENT OF FIRST-TO-MARKET CANDIDATE MAX-001
MAXONA Pharmaceuticals today announced that it has emerged from stealth with the completion of the U.S. Phase 1 clinical ...
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial
MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...
Hosted on MSN6mon
Annovis Bio Gains FDA Approval for New Form of Neurodegenerative Drug
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future clinical trials.